The placebo will be manufactured based on the PRD9241568 specifications to match the characteristics (appearance clinical trials

Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin

This study is looking into a new treatment, ACOU085, to see if it can prevent hearing loss in men with testicular cancer who are having cisplatin chemotherapy. Researchers want to know if it's safe, if people can tolerate it, and if it works.